Despite significant progress in multiple myeloma treatment with a range of biological drugs and their combinations—such as IMiDs (BMS REVLIMID, POMALYST/IMNOVID), anti-CD38 monoclonal antibody drugs (DARZALEX, SARCLISA), the anti-SLAM7 monoclonal antibody (AbbVie and BMS multiple myeloma drug EMPLICITI), and new proteasome inhibitors (KYPROLIS, NINLARO)—relapse after initial therapy remains a common issue for many patients.
In frontline clinical trials for multiple myeloma, Janssen multiple myeloma drug DARZALEX has proven to be effective and is now considered the standard of care. It has surpassed expectations in terms of both efficacy and safety and is anticipate...
